$CATX
Perspective Therapeutics, Inc. Stock $catx

$catx Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000114420416080050 Filed on February 09, 2016

Income Statement

Concept	2016 Q1	2015 Q4	2014 Q4
Revenue	$1.198M	$1.189M	$1.066M
YoY Change	3.44%	11.58%	-1.83%
Cost Of Revenue	$1.132M	$1.162M	$1.104M
YoY Change	2.64%	5.3%	-1.41%
Gross Profit	$66.00K	$30.00K	-$37.96K
YoY Change	19.57%	-179.02%	11.97%
Gross Profit Margin	5.51%	2.52%	-3.56%
Selling, General & Admin	$1.211M	$1.379M	$841.7K
YoY Change	25.52%	63.83%	0.15%
% of Gross Profit	1834.85%	4596.67%
Research & Development	$183.0K	$58.00K	$140.6K
YoY Change	29.42%	-58.76%	-17.29%
% of Gross Profit	277.27%	193.33%
Depreciation & Amortization	$140.0K	$137.5K	$135.2K
YoY Change	0.0%	1.74%	-24.9%
% of Gross Profit	212.12%	458.44%
Operating Expenses	$1.394M	$1.437M	$982.4K
YoY Change	26.02%	46.28%	-2.78%
Operating Profit	-$1.327M	-$1.410M	-$1.020M
YoY Change	26.26%	38.19%	-2.3%
Interest Expense	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
% of Operating Profit
Other Income/Expense, Net	$132.0K	$99.00K	$113.4K
YoY Change	35.44%	-12.67%	-3.44%
Pretax Income	-$1.200M	-$1.310M	-$910.0K
YoY Change	26.32%	43.96%	-2.15%
Income Tax
% Of Pretax Income
Net Earnings	-$1.195M	-$1.312M	-$907.0K
YoY Change	25.32%	44.66%	-2.16%
Net Earnings / Revenue	-99.75%	-110.34%	-85.11%
Basic Earnings Per Share
Diluted Earnings Per Share	-$21.81K	-$23.81K	-$16.58K
COMMON SHARES
Basic Shares Outstanding	55.01M shares	55.01M shares	54.87M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2015 Q4	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.61M	$12.60M	$11.38M
YoY Change	14.27%	10.72%	158.05%
Cash & Equivalents	$5.694M	$679.0K	$1.337M
Short-Term Investments	$5.910M	$11.92M	$10.05M
Other Short-Term Assets	$290.0K	$220.0K	$220.0K
YoY Change	31.82%	0.0%	37.5%
Inventory	$457.3K	$476.7K	$411.4K
Prepaid Expenses
Receivables	$880.0K	$980.0K	$797.4K
Other Receivables	$5.098K	$8.715K	$10.98K
Total Short-Term Assets	$13.24M	$14.28M	$12.83M
YoY Change	11.36%	11.37%	116.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$415.7K	$335.8K	$761.4K
YoY Change	-37.02%	-55.9%	-43.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$5.190M	$5.160M	$10.10M
YoY Change	-48.87%	-48.91%
Other Assets	$222.5K	$233.0K	$250.9K
YoY Change	-65.76%	-7.13%	-4.49%
Total Long-Term Assets	$6.556M	$6.461M	$11.76M
YoY Change	-43.92%	-45.06%	419.64%
TOTAL ASSETS
Total Short-Term Assets	$13.24M	$14.28M	$12.83M
Total Long-Term Assets	$6.556M	$6.461M	$11.76M
Total Assets	$19.80M	$20.74M	$24.59M
YoY Change	-16.05%	-15.62%	200.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$730.0K	$680.0K	$490.0K
YoY Change	65.91%	38.78%	13.95%
Accrued Expenses	$480.0K	$400.0K	$450.0K
YoY Change	9.09%	-11.11%	7.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.212M	$1.079M	$941.9K
YoY Change	37.76%	14.53%	11.17%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.060M	$1.110M	$1.120M
YoY Change	-4.5%	-0.89%	31.76%
Total Long-Term Liabilities	$1.060M	$1.110M	$1.120M
YoY Change	-4.5%	-0.89%	31.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.212M	$1.079M	$941.9K
Total Long-Term Liabilities	$1.060M	$1.110M	$1.120M
Total Liabilities	$2.271M	$2.193M	$2.057M
YoY Change	14.25%	6.6%	21.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$65.26M	-$64.06M	-$59.74M
YoY Change	7.51%	7.23%	10.05%
Common Stock	$82.78M	$82.62M	$54.88K
YoY Change	150731.64%	150441.23%	42.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00	$8.390K	$8.390K
YoY Change	-100.0%	0.0%	0.0%
Treasury Stock Shares	0.000 shares	13.20K shares	13.20K shares
Shareholders Equity	$17.52M	$18.55M	$22.53M
YoY Change
Total Liabilities & Shareholders Equity	$19.80M	$20.74M	$24.59M
YoY Change	-16.06%	-15.62%	200.27%

Cashflow Statement

Concept	2016 Q1	2015 Q4	2014 Q4
OPERATING ACTIVITIES
Net Income	-$1.195M	-$1.312M	-$907.0K
YoY Change	25.32%	44.66%	-2.16%
Depreciation, Depletion And Amortization	$140.0K	$137.5K	$135.2K
YoY Change	0.0%	1.74%	-24.9%
Cash From Operating Activities	-$760.0K	-$810.0K	-$620.0K
YoY Change	-32.74%	30.65%	-27.06%
INVESTING ACTIVITIES
Capital Expenditures	-$210.0K	-$30.00K	-$40.00K
YoY Change	425.0%	-25.0%	100.0%
Acquisitions
YoY Change
Other Investing Activities	$5.980M	-$50.00K	-$70.00K
YoY Change	550.0%	-28.57%
Cash From Investing Activities	$5.760M	-$80.00K	-$110.0K
YoY Change	562.07%	-27.27%	450.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-10.00K	-10.00K
YoY Change		0.0%	0.0%
NET CHANGE
Cash From Operating Activities	-760.0K	-810.0K	-620.0K
Cash From Investing Activities	5.760M	-80.00K	-110.0K
Cash From Financing Activities	0.000	-10.00K	-10.00K
Net Change In Cash	5.000M	-900.0K	-740.0K
YoY Change	-2023.08%	21.62%	-15.91%
FREE CASH FLOW
Cash From Operating Activities	-$760.0K	-$810.0K	-$620.0K
Capital Expenditures	-$210.0K	-$30.00K	-$40.00K
Free Cash Flow	-$550.0K	-$780.0K	-$580.0K
YoY Change	-49.54%	34.48%	-30.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	11918558	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5226740	USD
CY2015Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	8715	USD
CY2015Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	19615	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	224819	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	263597	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	14283089	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	16325522	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	335753	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	574840	USD
CY2015Q4	us-gaap	Long Term Investments LongTermInvestments	5163615	USD
CY2015Q2	us-gaap	Long Term Investments LongTermInvestments	5106775	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181277	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181262	USD
CY2015Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	547287	USD
CY2015Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	569854	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	233011	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	245031	USD
CY2015Q4	us-gaap	Assets Assets	20744032	USD
CY2015Q2	us-gaap	Assets Assets	23003284	USD
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	681312	USD
CY2015Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	498253	USD
CY2015Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	78703	USD
CY2015Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	124131	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	153500	USD
CY2015Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	129500	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	72545	USD
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	212795	USD
CY2015Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	92653	USD
CY2015Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	127515	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1078713	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1092194	USD
CY2015Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	123000	USD
CY2015Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	181000	USD
CY2015Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	991310	USD
CY2015Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	947849	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	55014	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	54968	USD
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	8390	USD
CY2015Q2	us-gaap	Treasury Stock Value TreasuryStockValue	8390	USD
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	82467111	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61731507	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	20782241	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23003284	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	678906	USD
CY2015Q2	us-gaap	Short Term Investments ShortTermInvestments	9362574	USD
CY2015Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	1049041	USD
CY2015Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	975342	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	403955	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	476749	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	82566531	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64062205	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	18551009	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20744032	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	39734	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	63363	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	42907	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-73700	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-124275	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	72794	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	51683	USD
CY2015Q4	us-gaap	Liabilities Liabilities	2193023	USD
CY2015Q2	us-gaap	Liabilities Liabilities	2221043	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2330698	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1692816	USD
	isr	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	0	USD
	isr	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	8607	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	274200	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	305147	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	28098	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	15469	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	43461	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-10899	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-42104	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-61345	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	15120	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	183059	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-86534	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-45428	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	9947	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	24000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-33524	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-140250	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-89537	USD
	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	-34862	USD
	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	-12387	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1919907	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1757625	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	35113	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	48657	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	16078	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2296	USD
CY2014Q4	us-gaap	Gross Profit GrossProfit	-37964	USD
	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	6000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	3526999	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	5013694	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	6082983	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2200452	USD
	us-gaap	Gross Profit GrossProfit	110370	USD
	us-gaap	Gross Profit GrossProfit	-92766	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	202138	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	5058080	USD
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	56840	USD
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	4695282	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	15	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	27	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2664030	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4790648	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	46735	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	70411	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	145274	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	36103	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	205053	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4547834	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6343220	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7680073	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1336853	USD
	isr	Supplemental Common Stock Warrant Liability Reclassification SupplementalCommonStockWarrantLiabilityReclassification	0	USD
	isr	Supplemental Common Stock Warrant Liability Reclassification SupplementalCommonStockWarrantLiabilityReclassification	17000	USD
CY2015Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1189008	USD
CY2014Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1065585	USD
CY2015Q4	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1162097	USD
CY2014Q4	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1103549	USD
CY2015Q4	us-gaap	Gross Profit GrossProfit	26911	USD
CY2015Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	58235	USD
CY2014Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	140627	USD
CY2015Q4	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	254471	USD
CY2014Q4	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	303783	USD
CY2015Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1124683	USD
CY2014Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	537940	USD
CY2015Q4	us-gaap	Operating Expenses OperatingExpenses	1437389	USD
CY2014Q4	us-gaap	Operating Expenses OperatingExpenses	982350	USD
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1410478	USD
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1020314	USD
CY2015Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	55890	USD
CY2014Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	72360	USD
CY2015Q4	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	43000	USD
CY2014Q4	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	41000	USD
CY2015Q4	us-gaap	Interest Expense InterestExpense	0	USD
CY2014Q4	us-gaap	Interest Expense InterestExpense	0	USD
CY2015Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	98890	USD
CY2014Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	113360	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-1311588	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-906954	USD
CY2015Q4	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2658	USD
CY2014Q4	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2658	USD
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1314246	USD
CY2014Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-909612	USD
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2014Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2015Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55013553	shares
CY2014Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54883445	shares
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2450330	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2107686	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2339960	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	317237	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	532892	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y3M25D
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	488604	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	5316	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	5316	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2336014	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7114836	USD
	us-gaap	Depreciation Depreciation	274200	USD
	us-gaap	Depreciation Depreciation	305147	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	657526	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1876395	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1113891	USD
	us-gaap	Operating Expenses OperatingExpenses	2611425	USD
	us-gaap	Operating Expenses OperatingExpenses	2088654	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2501055	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2181420	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	113307	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	145055	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	58000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	347000	USD
	us-gaap	Interest Expense InterestExpense	950	USD
	us-gaap	Interest Expense InterestExpense	3451	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	170357	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1698132	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55013227	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54875749	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2546225	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2636497	shares
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	275456	USD
CY2015Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	143669	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	165726	USD
CY2015Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	204760	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	35567	USD
CY2015Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	55526	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7389036	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2126360	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2026059	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1709894	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M20D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y9M7D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y10M6D
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	235064	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	226839	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	231563	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.88
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.9
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.91
CY2015Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31051	USD
CY2014Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21453	USD
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	372627	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	21654	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	252308	USD
CY2015Q4	isr	Percentage Of Royalty Rate Payable PercentageOfRoyaltyRatePayable	0.01	pure
CY2015Q4	us-gaap	Area Of Land AreaOfLand	4.2	acre
	us-gaap	Payments To Acquire Land Held For Use PaymentsToAcquireLandHeldForUse	168000	USD
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	360800	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	133564	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	45994	shares
CY2015Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	385800	shares
CY2015Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.22
CY2015Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.17
	isr	Classofwarrantorrightexpiredinperiodweightedaverageexercisepriceofwarrantsorrights Classofwarrantorrightexpiredinperiodweightedaverageexercisepriceofwarrantsorrights	2
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	30000	USD
CY2015Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	30000	USD
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	192998329	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55013553	shares
	isr	Class Of Warrant Or Right Expired In Period ClassOfWarrantOrRightExpiredInPeriod	25000	shares
	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	6000	USD
	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	6000	USD
	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	6000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	IsoRay, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0000728387
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	ISR
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55013553	shares
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54967559	shares
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	13200	shares
CY2015Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	13200	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55013553	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54967559	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	192998329	shares
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	10632	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	10632	USD
	isr	Federal Deposit Insurance Corporation Limits On Deposits In Financial Institutions FederalDepositInsuranceCorporationLimitsOnDepositsInFinancialInstitutions	250000	USD
CY2015Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2000	USD
CY2014Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2000	USD
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="clear:both;WIDTH: 99.98%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="99%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">2.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><b> <font style="FONT-SIZE: 10pt">New Accounting Pronouncements</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes the revenue recognition requirements in FASB Accounting Standards Codification (ASC) Topic 605, Revenue Recognition. The guidance requires that an entity recognize revenue in a way that depicts the transfer of promised goods or services to customers in the amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods and services. The guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In July 2015, the FASB issued ASU No. 2015-11 Inventory. The guidance requires an entity’s management to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early application is permitted.  The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments Overall. The guidance requires an entity’s management to measure equity investments except those accounted for under the equity method of accounting or those that result in consolidation of the investee to be measured at fair value; simplifies the impairment assessment of equity investments; eliminates the requirement to disclose the fair value of financial instruments measured at amortized cost for non-public entities: eliminates the requirement for a public entity to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements; and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early application is not permitted except as contained in the early adoption guidance.  The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	63363	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42907	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7724789	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7689676	USD
CY2015Q4	us-gaap	Depreciation Depreciation	137531	USD
CY2014Q4	us-gaap	Depreciation Depreciation	135176	USD
CY2015Q4	us-gaap	Other Liabilities OtherLiabilities	300000	USD
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015Q4	isr	Number Of Employees Commitment NumberOfEmployeesCommitment	25	pure

Files In Submission

Name	View Source	Status
0001144204-16-080050-index-headers.html	Edgar Link	pending
0001144204-16-080050-index.html	Edgar Link	pending
0001144204-16-080050.txt	Edgar Link	pending
0001144204-16-080050-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
isr-20151231.xml	Edgar Link	completed
isr-20151231.xsd	Edgar Link	pending
isr-20151231_cal.xml	Edgar Link	unprocessable
isr-20151231_def.xml	Edgar Link	unprocessable
isr-20151231_lab.xml	Edgar Link	unprocessable
isr-20151231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v430539_10q.htm	Edgar Link	pending
v430539_ex10-87.htm	Edgar Link	pending
v430539_ex10-88.htm	Edgar Link	pending
v430539_ex31-1.htm	Edgar Link	pending
v430539_ex31-2.htm	Edgar Link	pending
v430539_ex32.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CATX
Perspective Therapeutics, Inc. Stock $catx

2016 Q1 Form 10-Q Financial Statement

#000114420416080050 Filed on February 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX Perspective Therapeutics, Inc. Stock $catx

2016 Q1 Form 10-Q Financial Statement

#000114420416080050 Filed on February 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX
Perspective Therapeutics, Inc. Stock $catx